FDA Meeting Seen As Pivotal For Tissue-Agnostic Cancer Drug Pipeline

On the heels of FDA's first approval of a tissue-agnostic cancer treatment, cancer research advocates are eagerly awaiting an FDA public workshop scheduled for May 9 on the scientific and regulatory issues associated with granting orphan drug designation to these therapies. The head of a major cancer think tank hopes the meeting will provide some clarity on whether these treatments, which in aggregate can treat more patients than traditional orphan drugs, will still be eligible for the designation. While the...